Clinical Data Abivax slides on phase 3 data in ulcerative colitis PharmaphorumShares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.Immunology & InflammationRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Deep Science Ventures and MDC partner to accelerate brain treatmentsNext: AbiVax falls as safety worries cloud ‘landmark’ immune drug results Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
